OncoMatch/Clinical Trials/NCT06807606
Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation
Is NCT06807606 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for hematologic malignancies.
Treatment: Drugs Cyclophosphamide · Fludarabine · Thiotepa · Tacrolimus · Mycophenolate mofetil — The goal of this clinical research study is to learn if intermediate-intensity conditioning therapy followed by a cord blood transplant can help to control high-risk hematological malignancies in patients who need a second allogeneic stem cell transplantation.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Prior therapy
Must have received: stem cell transplant — allogeneic
Lab requirements
Kidney function
Calculated creatinine clearance > 50 ml/min
Liver function
Bilirubin < 2 mg/dL (unless benign congenital hyperbilirubinemia or hemolysis); ALT < 5 x upper limit of normal (ULN)
Cardiac function
Left ventricular ejection fraction (MOD-bp) > 50%
Calculated creatinine clearance > 50 ml/min. Bilirubin < 2 mg/dL (unless benign congenital hyperbilirubinemia or hemolysis). ALT < 5 x upper limit of normal (ULN). Left ventricular ejection fraction (MOD-bp) > 50%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of Texas M. D. Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify